Retatrutide is an investigational peptide studied as a triple receptor agonist that activates the GLP-1, GIP, and glucagon receptors. It remains under research and is not an approved product. It is sold for laboratory and research use only.

What receptors does retatrutide target?

Retatrutide is designed to engage three receptors at once: GLP-1 and GIP, both incretin pathways involved in glucose and appetite signaling, plus the glucagon receptor, which is involved in energy expenditure and hepatic metabolism. This three-way profile is what distinguishes it from single- and dual-agonist peptides.

How is retatrutide different from tirzepatide and semaglutide?

Semaglutide is a single GLP-1 receptor agonist, tirzepatide is a dual GIP/GLP-1 agonist, and retatrutide adds a third target, the glucagon receptor, making it a triple agonist. Each additional receptor changes the metabolic profile studied in research.

How is retatrutide reconstituted for research?

Retatrutide ships as a lyophilized powder and is reconstituted with bacteriostatic water. The water volume sets the concentration in mg/mL. A reconstitution and dosage calculator converts vial size, water volume, and target amount into exact syringe units.

Research Overview · Research Use Only

Retatrutide: research overview

Retatrutide is an investigational peptide studied as a triple receptor agonist - it is designed to activate the GLP-1, GIP, and glucagon receptors together. That three-way profile is what sets it apart from the single- and dual-agonist peptides that came before it, and it's why retatrutide has become one of the most closely watched compounds in metabolic research.

Research use only. Retatrutide is an investigational compound and is not an approved product. This page is educational reference for laboratory research and is not medical advice or human-dosing guidance. All products are sold strictly for research use and are not for human consumption.

What is retatrutide?

Retatrutide is a synthetic peptide in the incretin class of research compounds. Where earlier peptides act on one or two metabolic receptors, retatrutide is engineered to engage three at once. In the scientific literature it is often described as a "triple G" agonist, referring to GLP-1, GIP, and glucagon.

The triple-receptor mechanism

GLP-1 receptor - an incretin pathway central to glucose-dependent insulin signaling and appetite regulation. This is the same receptor semaglutide targets.
GIP receptor - a second incretin pathway that research suggests works synergistically with GLP-1. Tirzepatide adds this target.
Glucagon receptor - involved in energy expenditure and hepatic (liver) metabolism. Adding this third target is what makes retatrutide unique among the metabolic peptides.

Retatrutide vs. tirzepatide vs. semaglutide

The three most-studied metabolic peptides differ mainly in how many receptors they engage:

Peptide	Receptor targets	Class
Semaglutide	GLP-1	Single agonist
Tirzepatide	GIP + GLP-1	Dual agonist
Retatrutide	GLP-1 + GIP + glucagon	Triple agonist

Read the companion overviews for tirzepatide and browse the full research peptide catalog for current options and pricing.

Forms & handling in the lab

Retatrutide ships as a lyophilized (freeze-dried) powder. We carry it in several vial sizes - including 10 mg, 15 mg, 20 mg, and a 40 mg peptide-pen kit - so researchers can match vial size to their protocol. Before use it is reconstituted with bacteriostatic water; the water volume you choose determines the concentration in mg/mL.

🧮

Calculate concentration & syringe units

Enter vial size, water volume, and target amount for exact figures.

Storage & stability

Lyophilized powder - most stable form; keep frozen or refrigerated and protected from light until reconstituted.
Reconstituted solution - refrigerate at roughly 2–8 °C; as a general research guideline, use within about 28 days.
Avoid repeated freeze–thaw cycles, heat, and shaking, all of which can degrade the peptide.

Frequently asked questions

What is retatrutide?

An investigational triple receptor agonist studied for its combined action on the GLP-1, GIP, and glucagon receptors. It is under research, not an approved product, and sold for laboratory research use only.

What makes it a "triple" agonist?

It engages three receptors at once - GLP-1, GIP, and glucagon - whereas semaglutide targets one and tirzepatide targets two.

How is it different from tirzepatide?

Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds the glucagon receptor as a third target. See the tirzepatide overview for a side-by-side.

How is retatrutide reconstituted?

With bacteriostatic water; the water volume sets the mg/mL concentration. Our calculator and reconstitution guide walk through the math.

Related guides

Retatrutide & more in the catalog

Live inventory and exact pricing on retatrutide vial sizes and the peptide-pen kit.

View catalog → Place an order →

Research Use Only. All products are sold strictly for laboratory and research purposes and are not for human consumption, medical, veterinary, or diagnostic use. Your Peptide Partner is not a compounding pharmacy under Section 503A, nor an outsourcing facility under Section 503B, of the Federal Food, Drug, and Cosmetic Act. Retatrutide is an investigational compound and is not an approved product. This page is educational reference only - it is not medical advice or dosing guidance. By ordering you confirm you are a qualified purchaser and agree to our Terms & Conditions; all orders are subject to review and acceptance. See our Research Compliance policy.